ARVN Key Statistics, Chart & Performance
The current stock price of ARVN is 11.81 USD. In the past month the price increased by 16.47%. In the past year, price decreased by -54.44%.
ARVN Latest News, Press Relases and Analysis
ARVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.11 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.73B | ||
| MRK | MERCK & CO. INC. | 11.56 | 252.74B | ||
| PFE | PFIZER INC | 7.9 | 143.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.12B | ||
| ZTS | ZOETIS INC | 20.07 | 56.08B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.71 | 23.03B | ||
| VTRS | VIATRIS INC | 4.59 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.56 | 11.24B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.66 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.51B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.37B |
Related stock screener links
About ARVN
Company Profile
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 430 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Company Info
ARVINAS INC
5 Science Park
New Haven CONNECTICUT 06511 US
CEO: John Houston
Employees: 430
Phone: 12035351456
ARVINAS INC / ARVN FAQ
What does ARVINAS INC do?
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 430 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
What is the stock price of ARVINAS INC today?
The current stock price of ARVN is 11.81 USD. The price decreased by -6.16% in the last trading session.
What is the dividend status of ARVINAS INC?
ARVN does not pay a dividend.
What is the ChartMill rating of ARVINAS INC stock?
ARVN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ARVN stock?
ARVN stock is listed on the Nasdaq exchange.
What sector and industry does ARVINAS INC belong to?
ARVINAS INC (ARVN) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the number of employees for ARVINAS INC?
ARVINAS INC (ARVN) currently has 430 employees.
ARVN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ARVN. When comparing the yearly performance of all stocks, ARVN is a bad performer in the overall market: 60.34% of all stocks are doing better.
ARVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARVN. While ARVN seems to be doing ok healthwise, there are quite some concerns on its profitability.
ARVN Financial Highlights
Over the last trailing twelve months ARVN reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 82.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.92% | ||
| ROE | -10.35% | ||
| Debt/Equity | 0 |
ARVN Forecast & Estimates
26 analysts have analysed ARVN and the average price target is 13.08 USD. This implies a price increase of 10.75% is expected in the next year compared to the current price of 11.81.
For the next year, analysts expect an EPS growth of 55.22% and a revenue growth -2.7% for ARVN